CorMedix Fixed Asset Turnover from 2010 to 2024

CRMD Stock  USD 8.57  0.30  3.38%   
CorMedix's Fixed Asset Turnover is decreasing over the years with stable fluctuation. Fixed Asset Turnover is expected to dwindle to 0.03. During the period from 2010 to 2024 CorMedix Fixed Asset Turnover annual values regression line had geometric mean of  0.27 and mean square error of  3.65. View All Fundamentals
 
Fixed Asset Turnover  
First Reported
2010-12-31
Previous Quarter
0.0315
Current Value
0.03
Quarterly Volatility
1.87057186
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CorMedix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CorMedix's main balance sheet or income statement drivers, such as Interest Expense of 32.6 K, Selling General Administrative of 37.6 M or Research Development of 10.2 M, as well as many indicators such as Price To Sales Ratio of 1.6 K, Dividend Yield of 0.0179 or PTB Ratio of 2.87. CorMedix financial statements analysis is a perfect complement when working with CorMedix Valuation or Volatility modules.
  
Check out the analysis of CorMedix Correlation against competitors.
For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.

Latest CorMedix's Fixed Asset Turnover Growth Pattern

Below is the plot of the Fixed Asset Turnover of CorMedix over the last few years. It is CorMedix's Fixed Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CorMedix's overall financial position and show how it may be relating to other accounts over time.
Fixed Asset Turnover10 Years Trend
Pretty Stable
   Fixed Asset Turnover   
       Timeline  

CorMedix Fixed Asset Turnover Regression Statistics

Arithmetic Mean1.37
Geometric Mean0.27
Coefficient Of Variation136.16
Mean Deviation1.57
Median0.08
Standard Deviation1.87
Sample Variance3.50
Range5.5219
R-Value(0.18)
Mean Square Error3.65
R-Squared0.03
Significance0.53
Slope(0.07)
Total Sum of Squares48.99

CorMedix Fixed Asset Turnover History

2024 0.03
2023 0.0315
2022 0.0274
2021 0.0804
2020 0.21
2019 2.23
2018 2.67

About CorMedix Financial Statements

CorMedix stakeholders use historical fundamental indicators, such as CorMedix's Fixed Asset Turnover, to determine how well the company is positioned to perform in the future. Although CorMedix investors may analyze each financial statement separately, they are all interrelated. For example, changes in CorMedix's assets and liabilities are reflected in the revenues and expenses on CorMedix's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CorMedix. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Fixed Asset Turnover 0.03  0.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:
Check out the analysis of CorMedix Correlation against competitors.
For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.80)
Revenue Per Share
0.212
Quarterly Revenue Growth
(0.47)
Return On Assets
(0.38)
Return On Equity
(0.65)
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.